文献速递临床微生物分子诊断临床免疫

脓毒症诊断与监测:创新技术前沿

Sepsis diagnosis and monitoring: Frontiers in innovative technology.
PubMed 文献 · Clin Chim Acta · 2025-10-09

该综述通过检索PubMed等数据库,比较传统血培养与实时PCR、MALDI-TOF质谱、新型生物标志物平台等快速诊断技术,指出快速分子检测可在数小时内出结果,有助于早期靶向治疗和抗菌药物管理,从而改善脓毒症患者预后。

要点

  • 血培养仍是基石,但周转时间长、敏感性有限。
  • 快速分子检测(PCR、MALDI-TOF)可在数小时内出结果。
  • 降钙素原是证据最充分的生物标志物,presepsin等新标志物有前景。

核心结论

  • 将快速分子诊断与生物标志物监测整合入临床流程,可增强脓毒症早期识别、支持抗菌药物管理并改善患者生存。

研究设计与样本

  • 综述类文章,通过PubMed、Scopus、Web of Science和Google Scholar数据库,以「sepsis」和「diagnostic strategies」等关键词进行广泛文献检索。

主要发现

  • 传统血培养周转时间长且敏感性降低。
  • 快速分子检测(PCR、MALDI-TOF)和生物传感器床旁平台可在数小时内提供结果,支持更早的靶向治疗。
  • 降钙素原是最成熟的生物标志物,presepsin、CXCL5和circRNAs等新标志物显示出有前景的诊断和预后潜力。

关键数值与推荐

  • 快速分子检测(PCR、MALDI-TOF)和生物传感器床旁平台可在数小时内出结果。
  • 降钙素原仍是最成熟的生物标志物。
  • 生物标志物监测包括sTREM-1、IL-6和PCT。

临床怎么用

  • 在临床工作流程中整合快速分子检测和生物标志物监测,以支持脓毒症早期检测和抗菌药物管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One of the most common hospital-associated infections, especially in the ICU, is sepsis, and its early detection is a significant issue that health care systems must contend with. Effective treatment of sepsis requires early diagnosis and rapid therapeutic intervention. The early detection of this life-threatening condition is significantly improved not only by identifying drug-resistant pathogens but also by detecting unique immune response biomarkers that arise upon pathogen invasion, thus creating a critical early warning system. The methodology involves advanced molecular diagnostic tools, such as real-time PCR, MALDI-TOF mass spectrometry, and novel biomarker detection platforms. These methods enable faster identification of pathogens and biomarkers, enhancing the accuracy and speed of sepsis diagnosis. We also discuss the integration of these technologies with clinical workflows, considering their impact on patient outcomes and healthcare efficiency. In this paper, we review novel and rapid sepsis diagnostic techniques compared to traditional methods, emphasizing the significance and efficiency of the emerging technologies. An extensive review of the literature was conducted through databases such as PubMed, Scopus, Web of Science, and Google Scholar with keywords such as "sepsis" and "diagnostic strategies" to identify the most suitable articles for this review. Effective management of sepsis, a complex and deadly disease, relies on knowledge and application of rapid diagnostic techniques, such as new analytic tools, for successful treatment and improved patient outcomes. Advanced molecular diagnosis and clinical trials are maximizing therapeutic control with biomarker tracking (sTREM-1, IL-6, PCT) and improving diagnostic accuracy. Introducing new technologies in molecular diagnosis, analysis, and clinical management is crucial to improve septic shock patient outcomes. Our review highlights that while traditional methods such as blood culture remain essential, they are limited by long turnaround times and reduced sensitivity. Rapid molecular assays (PCR, MALDI-TOF) and biosensor-based point-of-care platforms provide results within hours, enabling earlier targeted treatment. Among biomarkers, procalcitonin remains the most established, but newer candidates such as presepsin, CXCL5, and circRNAs show promising diagnostic and prognostic potential. Integrating these innovative technologies into clinical workflows can enhance early detection, support antimicrobial stewardship, and ultimately improve patient survival.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Mirmotahari SA, Maghsoudi AS, Amini M, et al. Sepsis diagnosis and monitoring: Frontiers in innovative technology. Clin Chim Acta. 2025. PMID: 41067487. doi:10.1016/j.cca.2025.120640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。